GenMont Biotech Incorporation Balance Sheet Health
Financial Health criteria checks 5/6
GenMont Biotech Incorporation has a total shareholder equity of NT$1.4B and total debt of NT$22.3M, which brings its debt-to-equity ratio to 1.5%. Its total assets and total liabilities are NT$1.7B and NT$204.1M respectively. GenMont Biotech Incorporation's EBIT is NT$7.0M making its interest coverage ratio -0.8. It has cash and short-term investments of NT$328.3M.
Key information
1.5%
Debt to equity ratio
NT$22.35m
Debt
| Interest coverage ratio | -0.8x |
| Cash | NT$328.30m |
| Equity | NT$1.45b |
| Total liabilities | NT$204.06m |
| Total assets | NT$1.65b |
Recent financial health updates
No updates
Recent updates
We Think That There Are More Issues For GenMont Biotech Incorporation (TWSE:3164) Than Just Sluggish Earnings
Mar 19
Should You Or Shouldn't You: A Dividend Analysis on GenMont Biotech Incorporation (TPE:3164)
Apr 04GenMont Biotech Incorporation's(TPE:3164) Share Price Is Down 26% Over The Past Five Years.
Feb 14
Is GenMont Biotech Incorporation's (TPE:3164) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 24Tread With Caution Around GenMont Biotech Incorporation's (TPE:3164) 3.5% Dividend Yield
Jan 03Are GenMont Biotech Incorporation's (TPE:3164) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 08Financial Position Analysis
Short Term Liabilities: 3164's short term assets (NT$465.5M) exceed its short term liabilities (NT$146.4M).
Long Term Liabilities: 3164's short term assets (NT$465.5M) exceed its long term liabilities (NT$57.7M).
Debt to Equity History and Analysis
Debt Level: 3164 has more cash than its total debt.
Reducing Debt: 3164's debt to equity ratio has increased from 0% to 1.5% over the past 5 years.
Debt Coverage: 3164's debt is well covered by operating cash flow (154.8%).
Interest Coverage: 3164 earns more interest than it pays, so coverage of interest payments is not a concern.